Using Biologics to Reduce Long-Term Corticosteroid Use in Pyoderma Gangrenosum: Real-World Evidence From Two Centres

使用生物制剂减少坏疽性脓皮病患者长期使用皮质类固醇:来自两个中心的真实世界证据

阅读:2

Abstract

BACKGROUND: Pyoderma gangrenosum (PG) is a challenging inflammatory skin disorder. While corticosteroids offer a rapid response, their long-term risks necessitate alternative treatments. OBJECTIVE: To compare the long-term effectiveness of biologic therapies versus systemic corticosteroids in PG management. METHODS: A retrospective analysis of 15 PG patients from two centres (Sydney, Australia, and Milan, Italy) was conducted. Patients received either biologic therapies (n = 8) or corticosteroids (n = 7), with ulcer healing outcomes assessed at weeks 16, 28-32 and 54. RESULTS: At week 16, corticosteroids led to faster ulcer reduction and re-epithelialisation. However, biologic-treated patients showed sustained improvement over time, supporting their role in long-term PG management. CONCLUSION: While corticosteroids provide an initial advantage, biologics demonstrate gradual and sustained efficacy, suggesting a long-term therapeutic role in PG treatment.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。